The TRIDENT-1 trial (NCT03093116) evaluated repotrectinib in locally advanced or metastatic NSCLC patients with a positive ROS1 status, showing promising results in both inhibitor-naïve and pretreated patients, with effective responses observed against specific mutations [119]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.